Noninvasive prenatal testing for aneuploidy-ready for prime time?

American Journal of Obstetrics and Gynecology

Volumn 206, Issue 4, 2012, Pages 269-275

  Chitty, Lyn S ^a   Hill, Melissa ^a,b   White, Helen ^d   Wright, David ^e   Morris, Stephen ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE FETAL DNA; DNA; UNCLASSIFIED DRUG;

ANEUPLOIDY; CHORION VILLUS SAMPLING; COST; DIAGNOSTIC ACCURACY; DOWN SYNDROME; EDITORIAL; GENETIC COUNSELING; HUMAN; INVASIVE PRENATAL DIAGNOSIS; INVASIVE PROCEDURE; MATERNAL PLASMA; MEDICAL ETHICS; NON INVASIVE PROCEDURE; NONINVASIVE PRENATAL DIAGNOSIS; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; TRISOMY 18; TRISOMY 21;

CHROMOSOMES, HUMAN, PAIR 18; DNA; DOWN SYNDROME; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; TRISOMY;

EID: 84859350834     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2012.02.021     Document Type: Editorial

References (68)

1. Bianchi DW. From Michael to microarrays: 30 years of studying fetal cells and nucleic acids in maternal blood. Prenat Diagn 2010;30:622-3.
2. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7. (Pubitemid 27343304)
3. Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2011 Oct 13 [epub ahead of print].
4. Bustamante-Aragones A, Rodriguez de Alba M, Gonzalez-Gonzalez C, et al. Fetal sex determination in maternal blood from the seventh week of gestation and its role in diagnosing hemophilia in the fetuses of female carriers. Haemophilia 2008;14:593-8. (Pubitemid 351638749)
5. Scheffer PG, van der Schoot CE, Page-ChristiaensGC,et al. Reliability of fetal sex determination using maternal plasma. Obstet Gynecol 2010;115:117-26.
6. Hill M, Finning K, Martin P, et al. Non-invasive prenatal determination of fetal sex: translating research into clinical practice. Clin Genet 2011;80:68-75.
7. Hill M, Taffinder S, Chitty LS, Morris S. Incremental cost of non-invasive prenatal diagnosis versus invasive prenatal diagnosis of fetal sex in England. Prenat Diagn 2011;31:267-73.
8. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401.
9. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.
10. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011;306:627-36.
11. Verweij EJ, van den Oever JM, de Boer MA, Boon EM, Oepkes D. Diagnostic accuracy of noninvasive detection of fetal trisomy 21 in maternal blood: a systematic review. Fetal Diagn Ther 2011 Nov 17 [epub ahead of print].
12. Benn PA, Borrell A, Cuckle H, et al. Prenatal detection of Down syndrome using massively parallel sequencing (MPS): a rapid response position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenat Diagn 2012;32:1-2.
13. Sparks AB,WangET, Struble CA, et al. Selective analysis of cell-freeDNAin maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32:3-9.
14. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:319.e1-9.
15. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:322.e1-5.
16. Lo YM, Tsui NB, Chiu RW, et al. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med 2007;13:218-23.
17. Tsui NB, Akolekar R, Chiu RW, et al. Synergy of total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of trisomy 21. Clin Chem 2010;56:73-81.
18. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A 2008;105:16266-71.
19. Fan HC, Quake SR. Sensitivity of noninvasive prenatal detection of fetal aneuploidy from maternal plasma using shotgun sequencing is limited only by counting statistics. PLoS One 2010;5:e10439.
20. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 2008;105:20458-63.
21. Ghanta S, Mitchell ME, Ames M, et al. Non-invasive prenatal detection of trisomy 21 using tandem single nucleotide polymorphisms. PLoS One 2010;5:e13184.
22. Tong YK, Jin S, Chiu RW, et al. Noninvasive prenatal detection of trisomy 21 by an epigenetic-genetic chromosome-dosage approach. Clin Chem 2010;56:90-8.
23. Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med 2011;17:510-3.
24. Deng YH, Yin AH, He Q, et al. Non-invasive prenatal diagnosis of trisomy 21 by reverse transcriptase multiplex ligation-dependent probe amplification. Clin Chem Lab Med 2011;49:641-6.
25. Chiu RW, Sun H, Akolekar R, et al. Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. Clin Chem 2010;56:459-63.
26. Sehnert AJ, Rhees B, Comstock D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing: of cell-free fetal DNA from maternal blood. Clin Chem 2011;57:1042-9.
27. Chen EZ, Chiu RW, Sun H, et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One 2011;6:e21791.
28. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205.e1-11.
29. Lau TK, Chen F, Pan X, et al. Noninvasive prenatal diagnosis of common fetal chromosomal aneuploidies by maternal plasmaDNAsequencing. J Matern Fetal Neonatal Med 2012 Feb 24 [epub ahead of print].
30. GenomeWeb. Aria kicks off clinical trial for non-invasive Down syndrome test. New York, NY: GenomeWeb LLC; Jan. 12, 2012. Available at: http://www.genomeweb.com/mdx/aria-kicks-clinical-trial-non-invasivedown- syndrome-test. Accessed Jan. 21, 2012.
31. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004;24:762-6. (Pubitemid 39468654)
32. American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins. ACOG practice bulletin: screening for fetal chromosome abnormalities. Obstet Gynecol 2007;109:217-26.
33. United Kingdom National Screening Committee. Antenatal screening - working standards for Down's syndrome screening 2007. Available at: http://fetalanomaly.screening.nhs.uk/standardsandpolicies. Accessed Jan. 30, 2012.
34. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15.
35. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
36. Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Scielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of pre-eclampsia: a systematic review. Obstet Gynecol Surv 2011;66:225-39.
37. Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 2011;29:148-54.
38. Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of pre-eclampsia and intrauterine growth restriction. Prenat Diagn 2010;30:293-308.
39. Clur SA, Van Brussel PM, Mathijssen IB, Pajkrt E, Ottenkamp J, Bilardo CM. Audit of 10 years of referrals for fetal echocardiography. Prenat Diagn 2011;31:1134-40.
40. Jouannic JM, Thieulin AC, Bonnet D, et al. Measurement of nuchal translucency for prenatal screening of congenital heart defects: a population- based evaluation. Prenat Diagn 2011;31:1264-9.
41. Souka AP, Von Kaisenberg CS, Hyett JA, Sonbek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005;192:1005-21. (Pubitemid 40487772)
42. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH. Prediction of early, intermediateandlate pre-eclampsia from maternal factors, biophysical-and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
43. Alamillo CM, Fiddler M, Pergament E. Increased nuchal translucency in the presence of normal chromosomes: what's next? Curr Opin Obstet Gynecol 2012 Jan 24 [epub ahead of print].
44. Ritchie K, Bradbury I, Slattery J, Wright D, Iqbal K, Penney G. Economic modelling of antenatal screening and ultrasound scanning programs for identification of fetal abnormalities. BJOG 2005;112:866-74. (Pubitemid 40896950)
45. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999;13:167-70. (Pubitemid 29176889)
46. Bishop AJ, Marteau TM, Armstrong D. Women and health care professionals'preferences for Down's syndrome screening tests: a conjoint analysis study. BJOG 2004;111:775-9. (Pubitemid 39061498)
47. Tischler R, Hudgins L, Blumenfeld YJ, Greely HT, Ormond KE. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn 2011;31:1292-9.
48. Huttly WJ, Wald NJ. An audit of the detection of trisomy 18 in prenatal screening for Down syndrome using the Combined test. Prenat Diagn 2011;31:1317.
49. Sørensen S, Momsen G, Sundberg K, Friis-Hansen L, Jørgensen FS. First-trimester risk calculation for trisomy 13, 18, and 21: comparison of the screening efficiency between 2 locally developed programs and commercial software. Clin Chem 2011;57:1023-31.
50. Fetal Anomaly Screening Programme 2011. Available at: http://fetalanomaly.screening.nhs.uk/T13and18consultation. Accessed Jan. 29, 2012.
51. Chitty LS, Kistler J, Akolekar R, Liddle S, Nicolaides K, Levett L. Multiplex ligation-dependent probe amplification (MLPA): a reliable alternative for fetal chromosome analysis? J Matern Fetal Neonatal Med 2011 Dec 6 [epub ahead of print].
52. Gruchy N, Decamp M, Richard N, et al. Array CGH analysis in high-risk pregnancies: comparing DNA from cultured cells and cell-free fetal DNA. Prenat Diagn 2011 Oct 24 [epub ahead of print].
53. Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH. Fetal nuchal translucencyscanandearly prenatal diagnosis ofchromosomalabnormalitiesby rapid aneuploidy screening: observational study. BMJ 2006;332:452-5.
54. Kagan KO, Chitty LS, Cicero S, Eleftheriades M, Nicolaides KH. Ultrasound findings before amniocentesis in selecting the method of analyzing the sample. Prenat Diagn 2007;27:34-9. (Pubitemid 46144338)
55. Wright CF. Cell-free fetal nucleic acids for non-invasive prenatal diagnosis. Report of the United Kingdom expert working group.PHGFoundation. Available at: http://wwwphgfoundationorg/reports/4985. Accessed Jan. 29, 2012.
56. de Jong A, Dondorp WJ, de Die-Smulders CE, Frints SG, de Wert GM. Non-invasive prenatal testing: ethical issues explored. Eur J Hum Genet 2010;18:272-7.
57. Deans Z, Newson AJ. Should non-invasiveness change informed consent procedures for prenatal diagnosis? Health Care Anal 2011;19:122-32.
58. Zamerowski ST, Lumley MA, Arreola RA, et al. Favorable attitudes toward testing for chromosomal abnormalities via analysis of fetal cells in maternal blood. Genet Med 2001;3:301-9.
59. Kooij L, Tymstra T, Berg P, et al. The attitude of women toward current and future possibilities of diagnostic testing in maternal blood using fetal DNA. Prenat Diagn 2009;29:164-8.
60. Kelly SE, Farrimond HR. Non-invasive prenatal genetic testing: a study of public attitudes. Public Health Genomics 2012;15:73-81.
61. Sayres LC, Allyse M, Norton ME, Cho MK. Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Prenat Diagn 2011;31:1070-6.
62. van den Berg M, Timmermans DR, Ten Kate LP, van Vugt JM, van der Wal G. Are pregnant women making informed choices about prenatal screening? Genet Med 2005;7:332-8. (Pubitemid 40827582)
63. Seror V, Ville Y. Prenatal screening for Down syndrome: women's involvement in decision-making and their attitudes to screening. Prenat Diagn 2009;29:120-8.
64. Benn PA, Chapman AR. Practical and ethical considerations of noninvasive prenatal diagnosis. JAMA 2009;301:2154-6.
65. Kobelka C, Mattman A, Langlois S. An evaluation of the decisionmaking process regarding amniocentesis following a screen-positive maternal serum screen result. Prenat Diagn 2009;29:514-9.
66. Newson AJ. Ethical aspects arising from non-invasive fetal diagnosis. Semin Fetal Neonatal Med 2008;13:103-8.
67. van den Heuvel A, Chitty L, Dormandy E, et al. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. Patient Educ Couns 2010;78:24-8.
68. Hall A, Bostanci A, Wright CF. Non-invasive prenatal diagnosis using cell-free fetal DNA technology: applications and implications. Public Health Genomics 2010;13:246-55.